You are here

Portage Biotech Inc.

Portage Biotech Inc.
Listing Exchange: 
CSE
Status: 
Delisted
Industry: 
Life Sciences
Symbol: 
PBT.U
CSE Index: 
Currency: 

Portage is a unique entity in the world of biotechnology, enabling research and development to produce more clinical programs and maximize potential returns by eliminating typical overhead costs associated with many biotechnology companies. We nurture the creation of early- to mid-stage, first- and best-in-class therapies for a variety of cancers, by providing funding, strategic business and clinical counsel, and shared services, to enable efficient, turnkey execution of commercially-informed development plans. Our portfolio encompasses nine subsidiary companies whose products or technologies have established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. In collaboration with our subsidiaries, we create viable product development strategies, to cost-effectively deliver best-in-class R&D, clinical trial design, and financial and project management, to ultimately build value and support commercial potential.

You are here

Portage Biotech Inc. (PBT.U)

SEDAR Information

Company Info

Address
6 Adelaide Street East
Suite 300
Toronto, ON M5C 1H6
Canada
Phone
416-737-7600
Email
ks@portagebiotech.com
Listing date
Monday, October 28, 2013
Transfer Agent
TSX Trust Company
Auditor
Marcum LLP

Capitalization

Issued & Outstanding: 
10987706
Reserved for Issuance: 
5958

Company Officers

Dr. Gregory Bailey, Chairman
Dr. Ian Walters, Chief Executive Officer
Allan Shaw, CFO

Bulletins

23/04/2021

2021-0438 - Delist - Portage Biotech Inc. (PBT.U)

le 23 avril/April 2021

At the request of the company the common shares of Portage Biotech Inc. will be delisted at market close on April 23, 2021.

The Company’s common shares will continue to trade on the NASDAQ Capital Market.

For further information please see the issuer’s press release.

___________________________